Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 1/2 3Phase 1 2Phase NA 1

Status

Completed 54Terminated 11Withdrawn 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Osteosarcoma 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 119Specimen Handling 104pembrolizumab 102Magnetic Resonance Spectroscopy 96fludarabine 92Biopsy 79Injections 53Nivolumab 41venetoclax 40Bevacizumab 40Fluorouracil 38Paclitaxel 37Cisplatin 36Cetuximab 35Carboplatin 35Gemcitabine 31fludarabine phosphate 30Radiotherapy 30Oxaliplatin 30Leucovorin 28Immunotherapy, Adoptive 25Drug Therapy 25Ipilimumab 24Azacitidine 23Irinotecan 21130-nm albumin-bound paclitaxel 21tislelizumab 20Temozolomide 20Radiation 20atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Sunitinib × Clear all
NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT03900793 2026-02-03

Losartan + Sunitinib in Treatment of Osteosarcoma

University of Colorado, Denver

Phase 1 Recruiting
41 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡